THE PATHWAY TO QUALITY CARE
Tuesday, June 11, 2019
REGISTRATION: 11:00 AM
LUNCH SYMPOSIUM: 11:15 AM - 12:45 PM
On-site registration is available.
3400 S Las Vegas Blvd
Las Vegas, NV 89109
STATEMENT OF NEED
The programs will focus on the coordinated application of a CLDF endorsed evidence-based algorithm in the in-patient and ambulatory setting with the goal of improving patient outcomes.
The initiative will be tailored to the specific needs of hospital-based health care professionals.
Upon completion of this educational activity, participants should be able to:
- Communicate the prevalence of HE and define the complications and consequences associated with chronic liver disease, with focus on HE
- Identify the importance of early recognition of and screening for HE and describe the screening methods
- Describe the economic, patient and caregiver burdens associated with cirrhosis and HE
- Apply techniques to properly treat HE patients, including strategies for successfully transitioning patients from inpatient HE care to outpatient HE care in order to prevent disease recurrence and hospital readmissions
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation have no relationships to disclose.
LEARNER ASSURANCE STATEMENT
The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
AMERICANS WITH DISABILITIES ACT
The event staff will be glad to assist you with any special requirements (i.e. physical, dietary, etc.). Please contact us prior to the event at 888-565-5321.
Dr. Sammy Saab is a professor in the departments of Internal Medicine and Surgery at the David Geffen School of Medicine. He is also head of outcomes research in hepatology at the Pfleger Liver Institute.
Dr. Saab received his BS, MD, and MPH degrees from UCLA. He completed his residency in internal medicine at the University of California at San Diego (UCSD) Medical Center and a fellowship in gastroenterology/hepatology at the UCLA Center for Health Sciences. He also served as chief medical resident at USCD. Dr. Saab is board certified in gastroenterology and transplant hepatology.
He has received honorary fellowship from several medical societies, including the American Gastroenterology Association (AGAF), the American Association for the Study of Liver Diseases (FAASLD), and the American College of Gastroenterology (ACG).
Dr. Saab is active in many local, national, and international committees. He served on the Medical Advisory Committee of the Ventura County/ West Valley Chapter of TRIO (2005-2012), Practice Guidelines Committee of the American Society of Transplantation (2006-2008), and the Educational Committee of the American Association for the Study of Liver Diseases (2004-2007). He is currently on the local and national medical board for the American Liver Foundation.
Dr. Saab was elected to the American Association for the Study of Liver Diseases Nominating Committee in 2014. He previously served as a member of the United Network for Organ Sharing Membership and Professional Standards Committee and Performance Analysis and Improvement Subcommittee. Dr. Saab was also an active member of the Minority Affairs Committee Member and Cultural Diversity for the American College of Gastroenterology.
Dr. Saab has been an investigator in numerous clinical trials, a frequently invited speaker worldwide, and leads an annual patient education seminar.
He has been named one of the "Best Doctors in America" and has received the Distinguished Achievement Award from his Division of Digestive Diseases.
Dr. Saab has published over 300 peer-reviewed manuscripts. He has authored many book chapters, editorials, abstracts, and poster presentations. Dr. Saab is on the editorial board of more than a dozen journals and is currently the Liver Section editor for the Journal of Clinical Gastroenterology.
Research Support: Conatus.
Speakers Bureau: AbbVie, Bayer, BMS, Dova, Eisai, Elixis, Gilead, Intercept and Salix Pharmaceuticals
Consultant: AbbVie, Bayer, Dova, Eisai, Elixis, Gilead, Intercept, and Salix Pharmaceuticals.